Sweat glands are switched on by acetylcholine acting on muscarinic receptors. Oxybutynin blocks those receptors, so the signal fails and the gland does not produce sweat. The same block relaxes an overactive bladder muscle, which is what the drug is actually approved for.
Because the receptor is used all over the body, so are the effects: salivary glands, the focusing muscle of the eye, the gut, and the bladder all respond the same way.
The distinguishing feature of oxybutynin is that it crosses the blood-brain barrier more readily than glycopyrrolate does. Muscarinic receptors in the brain are involved in memory and alertness, so blocking them there can produce drowsiness, foggy thinking, and — in older people — confusion. That single pharmacological difference is why glycopyrrolate is usually tried first for sweating, despite oxybutynin being cheaper and more widely stocked.
Pregnancy and breastfeeding data are limited; discuss it rather than assuming.
No routine blood tests are required. The monitoring that matters is clinical, and it is mostly about the brain, the bladder, and the heat.
Immediately, in practical terms. Immediate-release oxybutynin works within one to two hours of a dose and the effect fades across the day. You will know after the first dose whether it does anything for your sweating.
What takes a few weeks is dose-finding — climbing from 2.5 mg to whatever balance of benefit and dry mouth you can accept.
Sweating returns within a day, and the side effects disappear on the same timescale. There is no withdrawal, no taper, and no rebound.
That fast reversibility is the reason a two-week trial is a low-cost experiment. If it makes you foggy or dry-mouthed beyond what the benefit is worth, stopping costs you nothing but the return of the sweating.